Trapeznikov N N, Gorbunova V A, Erëmina L A, Siniukov P A, Kovalevskiĭ E E
Vopr Onkol. 1987;33(7):65-74.
The effectiveness of cis-diammine-dichloroplatinum (cisplatinum, platidiam, DDP) alone or as a component of combined treatment was evaluated in 85 patients with osteogenic sarcoma. The said drugs were used as adjuvants following radical surgery (group I-18 cases), in combined treatment of solitary and single lung metastases (group 2-7 cases) and in 60 patients with advanced tumors (group 3). An analysis of long-term results showed response in 30.8% in group 3. In group 2, application of chemotherapy plus surgery was followed by remissions of 2-46+-month duration (mean-13.9 months). In group I, 78.7% are expected to survive metastasis-free more than 12 months. Toxicity was moderate, with nausea and vomiting (87.1%), myelosuppression (52.8%), nephrotoxicity (48.6%) and alopecia (75.7%) being the most common side-effects.
对85例骨肉瘤患者评估了顺二氨二氯铂（顺铂、铂得隆、DDP）单独使用或作为联合治疗组成部分的疗效。上述药物在根治性手术后用作辅助治疗（第一组 - 18例），用于孤立性和单发性肺转移的联合治疗（第二组 - 7例）以及60例晚期肿瘤患者（第三组）。长期结果分析显示，第三组的缓解率为30.8%。在第二组中，化疗加手术治疗后缓解期为2 - 46±个月（平均13.9个月）。在第一组中，预计78.7%的患者无转移存活超过12个月。毒性为中度，最常见的副作用是恶心和呕吐（87.1%）、骨髓抑制（52.8%）、肾毒性（48.6%）和脱发（75.7%）。
